<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01087398</url>
  </required_header>
  <id_info>
    <org_study_id>HORCSCT-0905</org_study_id>
    <nct_id>NCT01087398</nct_id>
  </id_info>
  <brief_title>Hematopoietic Stem Cell Transplantation for Malignant Infantile Osteopetrosis</brief_title>
  <official_title>Hematopoietic Stem Cell Transplantation for Malignant Infantile Osteopetrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tehran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tehran University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and side effects of donor hematopoietic
      cells using chemotherapy regimen without total-body irradiation in children undergoing a
      hematopoietic stem cell transplant for Malignant infantile osteopetrosis. The blood stem
      cells will be derived from either related donor or unrelated umbilical cord blood or
      haploidentical donor.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2009</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">November 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival and Progressive Free Survival in patient with infantile Osteopetrosis who receive allogeneic HSCT</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>One year overall survival after allogeneic HSCT</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>One year Progressive Free Survival after allogeneic HSCT</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transplantation Related Mortality (TRM) after allogeneic HSCT</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute and chronic GVHD rate after allogeneic HSCT</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Osteopetrosis</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan, Cyclophosphamide, Thymoglobulin, Fludarabine (Conditioning regimen)</intervention_name>
    <description>For sibling full match:
Busulfan 16 mg/kg &gt;5year - 20 mg/kg &lt;5year po
Cyclophosphamide 200 mg/kg iv
For other related full match, sibling or other related with one antigen mismatch and umbilical cord blood:
Busulfan 16 mg/kg &gt;5year - 20 mg/kg &lt;5year po
Cyclophosphamide 200 mg/kg iv
ATG rabbit (Thymoglobulin) 10 mg/kg or ATG horse (Atgam) 40 mg/kg
For haploidentical:
Busulfan 16 mg/kg &gt;5year - 20 mg/kg &lt;5year po
Cyclophosphamide 200 mg/kg iv
Fludarabine 160 mg/m^2</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Systemic chemotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stem Cell Transplantation</intervention_name>
    <description>Patients undergoing Hematopoietic Stem Cell Transplantation from one of below source:
Sibling full match
Other related full match
Sibling or other related with 1 mismatch antigen
Cord Blood
Haploidentical</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>HSCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporin, Methotrexate (GVHD prophylaxis)</intervention_name>
    <description>Cyclosporin A 1.5 mg/kg/day iv from -2, then 3 mg/kg/day iv (from +7 in PBSCT and +11 in BMT or UCBT) then 9 mg/kg/day po
10 mg/m^2 iv day +1 then 6 mg/m^ iv day +3 and +6 (Not for UCBT)</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Graft-versus-host disease (GVHD) prophylaxis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Osteopetrosis confirm by bone biopsy and radiographic imaging

          -  Age up to 5 year old

        Exclusion Criteria:

          -  Carbonic Anhydrase II (CAII) deficiency osteopetrosis variant

          -  Creatinine clearance ≤ 40ml/min/1.73m^2 or RTA

          -  Bilirubin ≥ 3mg/dL

          -  SGPT ≥ 500 U/L

          -  Current severe infection

          -  Evidence of CNS involvement

          -  Morbidity such as blindness or deafness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amir Ali Hamidieh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hematology-Oncology and SCT Research Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amir Ali Hamidieh, MD</last_name>
    <phone>84902645</phone>
    <phone_ext>+98-21</phone_ext>
    <email>aahamidieh@sina.tums.ac.ir</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hematology-Oncology &amp; SCT Research Center</name>
      <address>
        <city>Tehran</city>
        <zip>14114</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amir Ali Hamidieh, MD</last_name>
      <phone>84902645</phone>
      <phone_ext>+98-21</phone_ext>
      <email>aahamidieh@sina.tums.ac.ir</email>
    </contact>
    <investigator>
      <last_name>Ardeshir Ghavamzadeh, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mahdi Jalili, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <link>
    <url>http://horcsct.tums.ac.ir</url>
    <description>Hematology-Oncology and Stem Cell Transplantation Research Center</description>
  </link>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2010</study_first_submitted>
  <study_first_submitted_qc>March 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2010</study_first_posted>
  <last_update_submitted>May 31, 2012</last_update_submitted>
  <last_update_submitted_qc>May 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteopetrosis</keyword>
  <keyword>HSCT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteopetrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

